CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 3, 2009, Pages 292-296

  Joseph, F G ^a   Hirst, C L ^a   Pickersgill, T P ^a   Ben Shlomo, Y ^b   Robertson, N P ^a   Scolding, N J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGOCLONAL BAND; AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SKIN MANIFESTATION; BLOOD; BRAIN; CEREBROSPINAL FLUID; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEUROLOGIC EXAMINATION; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGIC EXAMINATION; OLIGOCLONAL BANDS; PROGNOSIS; YOUNG ADULT;

EID: 61549102446     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.150896     Document Type: Article

References (36)

1. Andersson M, Varez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
2. Miller JR, Burke AM, Bever CT. Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. Ann Neurol 1983;13:53-8.
3. Farrell MA, Kaufmann JC, Gilbert JJ, et al. Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation. Neurology 1985;35:212-18.
4. Fukazawa T, Kikuchi S, Sasaki H, et al. The significance of oligoclonal bands in multiple sclerosis in Japan: relevance of immunogenetic backgrounds. J Neurol Sci 1998;158:209-14.
5. Pirttila T, Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 1995;92:468-71.
6. Stendahl-Brodin L, Link H. Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1980;43:102-5.
7. Zeman AZ, Kidd D, McLean BN, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:27-30.
8. Rudick RA, Schiffer RB, Schwetz KM, et al. Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol 1986;43:578-83.
9. Scolding N. The differential diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001 ;71 (Suppl 2):ii9-15.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
11. McDonald Wl, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
13. Schoenfeld DA. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
14. Imrell K, Landtblom AM, Hillert J, et al. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006;67:1062-4.
15. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
16. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey-Smith G, Altman D, eds. Systematic reviews in health care. London: BMJ, 2007:285-312.
17. Ratnaike S, Kilpatrick T, Tress B, et al. Cerebrospinal fluid biochemistry in the diagnosis of multiple sclerosis. Ann Clin Biochem 1990;27:195-8.
18. Langer-Gould A, Steinman L. What went wrong in the natalizumab trials? Lancet 2006;367:708-10.
19. Scolding NJ, Jayne DR, Zajicek JP, et al. The syndrome of cerebral vasculitis: recognition, diagnosis and management. Q J Med 1997;90:61-73.
20. Ferreira S, D'Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 2005;44:434-42.
21. Serdaroglu P. Behcet's disease and the nervous system. J Neurol 1998;245:197-205.
22. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis- diagnosis and management based on a large series. Q J Med 1999;92:103-17.
23. Alexander EL, Malinow K, Lejewski JE, et al. Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 1986;104:323-30.
24. Fulford KW, Catterall RD, Delhanty JJ, et al. A collagen disorder of the nervous system presenting as multiple sclerosis. Brain 1972;95:373-86.
25. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002;28:173-89.
26. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996;156:1421-5.
27. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
28. Moulin D, Paty DW, Ebers GC. The predictive value of cerebrospinal fluid electrophoresis in 'possible' multiple sclerosis. Brain 1983;106(Pt 4):809-16.
29. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
30. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-5.
31. Rudick RA, Jacobs L, Kinkel PR, et al. Isolated idiopathic optic neuritis. Analysis of free kappa-light chains in cerebrospinal fluid and correlation with nuclear magnetic resonance findings. Arch Neurol 1986;43:456-8.
32. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997;41:392-8.
33. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68.
34. Qin Y, Duquette P, Zhang Y, et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 2003;83:1081-8.
35. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006;180:3-8.
36. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann.Neurol 2006;59:880-92.